title: [Coat's disease treated with bevacizumab (Avastin)].
abstract: METHODS
  We report a case of Coats' disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN(TM)). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness.
  
  
  CONCLUSIONS
  The aetiology of Coats' disease remains uncertain, as does its optimal management. Although resolution of a case depends partially on age, and can even occur spontaneously on rare occasions, intravitreal injections of bevacizumab should be considered when planning treatment.
authors.affiliation: Asociación Para Evitar la Ceguera en México IAP Hospital Dr. Luis Sánchez Bulnes, Ciudad de México, México.
authors.forename: L G
authors.initials: LG
authors.lastname: Alvarez-Rivera
authors.forename: M L
authors.initials: ML
authors.lastname: Abraham-Marín
authors.forename: H J
authors.initials: HJ
authors.lastname: Flores-Orta
authors.forename: M
authors.initials: M
authors.lastname: Mayorquín-Ruiz
authors.forename: C F
authors.initials: CF
authors.lastname: Cortés-Luna
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D005260:Female; D006801:Humans; D012164:Retinal Diseases / Q000188:drug therapy*; D012171:Retinal Vessels; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab